Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Cathy Kelly
Two highly anticipated proposed rules in Medicare Part D are scheduled for near-term release.
US HHS officials Azar and O’Brien tell a National Academy of Medicine forum that an important element of the Trump Administration’s approach to lowering drug prices is eliciting voluntary change from market players.
Remicade, Procrit, Aranesp and biosimilars will be subject to step therapy in limited number of Medicare Advantage plans in 2019.
Premiums will average about $80 for enhanced plan, well above average $32.50 premium for basic stand-alone Medicare Part D coverage in 2019.
Policy update reverses approach announced in 2013 on the basis that physicians prefer peer-to-peer communications with global expert practitioners, firm explains.
Legislation headed to President Trump would also ban pharmacy "gag" clauses.